4/A: Herbalife CFO DeSimone Amends SAR Grant Price

Herbalife's Chief Financial Officer, John DeSimone, filed an amended Form 4 to correct the exercise price of 45,195 Stock Appreciation Rights.

Summary

• An amendment to a Form 4 was filed by John DeSimone, Chief Financial Officer of Herbalife Ltd. (HLF).
• The amendment corrects the exercise price of 45,195 Stock Appreciation Rights (SARs) granted on February 25, 2026.
• The corrected exercise price for the SARs is $19.26, which was previously reported as $10.51.
• These SARs were granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan.
• The SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service.
• The expiration date for these SARs is February 25, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The correction of an administrative error is a minor negative, but the underlying grant of SARs to the CFO is a standard positive for aligning incentives.

Positives

• The grant of 45,195 Stock Appreciation Rights to the CFO aligns management's incentives with shareholder value creation, as the SARs only gain value if the stock price appreciates.

Negatives

• The necessity of filing an amendment to correct a significant detail like the exercise price (from $10.51 to $19.26) suggests a potential administrative error in the initial regulatory disclosure.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the specified vesting schedule and expiration date of the Stock Appreciation Rights.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity-based awards like Stock Appreciation Rights (SARs), is a standard practice across industries to incentivize long-term performance and align executive interests with shareholder returns. The correction of an exercise price, while an administrative detail, underscores the importance of accuracy in regulatory filings.

Comparison to Industry Standards

• The grant of Stock Appreciation Rights (SARs) is a common form of equity compensation for executives, similar to stock options, used by companies like Coca-Cola (KO) and PepsiCo (PEP) to incentivize performance without immediate dilution.
• The vesting schedule of one-third increments over three years is a standard practice, comparable to vesting schedules seen at companies such as Nike (NKE) or Starbucks (SBUX) for their executive equity awards, promoting retention and long-term commitment.
• The exercise price of $19.26, being the market price at the time of grant, is typical for SARs, ensuring that the executive benefits only if the stock price appreciates, a practice consistent with best governance standards.

Corporate Governance

Related Party Transactions

• The grant of Stock Appreciation Rights to Chief Financial Officer John DeSimone constitutes a related party transaction, which is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The grant of SARs aligns the CFO's interests with shareholder value creation, as the SARs only gain value if the stock price increases. The amendment ensures accurate disclosure of executive compensation terms.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued service by John DeSimone to meet vesting conditions for the SARs on February 25, 2027, February 25, 2028, and February 25, 2029.

Key Dates

Recommendation

This filing is an administrative amendment to correct an executive compensation detail and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grant of SARs is a standard practice for executive incentives.

Keywords

Herbalife, HLF, Form 4/A, SEC Filing, Insider Trading, Stock Appreciation Rights, SARs, Executive Compensation, John DeSimone, CFO